Home
Covid-19
Tools
Introduction to the Tools
Model Government Use Licences
Model Uses of Paragraph 7 or “LDC Waiver”
Special Compulsory Licences for Export of Medicines
Options for Regional Economic Communities
Voluntary Licences
TRIPS Flexibilities Database
Resources
Briefs & Briefing Documents
Publications
Tools
Useful Links
All Resources
Blog
About
Sign in
Welcome!
Log into your account
your username
your password
Forgot your password?
Password recovery
Recover your password
your email
Search
Medicines Law & Policy
Research and resources on intellectual property and health
Home
Covid-19
Tools
Introduction to the Tools
Model Government Use Licences
Model Uses of Paragraph 7 or “LDC Waiver”
Special Compulsory Licences for Export of Medicines
Options for Regional Economic Communities
Voluntary Licences
TRIPS Flexibilities Database
Resources
Briefs & Briefing Documents
Publications
Tools
Useful Links
All Resources
Blog
About
Christopher Garrison
6 POSTS
0 COMMENTS
We need a Global Vaccines Taskforce, not just a British or European one
Christopher Garrison
-
February 24, 2021
What is the ‘know-how gap’ problem and how might it impact scaling up production...
Christopher Garrison
-
December 16, 2020
How the ‘Oxford’ Covid-19 vaccine became the ‘AstraZeneca’ Covid-19 vaccine
Christopher Garrison
-
October 5, 2020
Price, profit and the Covid-19 health technology pool: The example of remdesivir
Christopher Garrison
-
May 28, 2020
Never say never – Why the High Income Countries that opted-out from the Art....
Christopher Garrison
-
April 8, 2020
Urgent collective action to meet the challenge of this pandemic crisis: a coronavirus related...
Christopher Garrison
-
March 30, 2020